Skip to main content
Premium Trial:

Request an Annual Quote

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

In BMC Genomics, University of Oxford researchers consider epigenetic effects on CRISPR-Cas9 genome editing, particularly for off-target editing activity. With the help of an off-target database known as crisprSQL, coupled with machine learning methods for predicting off-target activity, the team tallied the consequences of 19 epigenetic features, including 13 nucleosome organization features found computationally and half a dozen epigenetic features determined experimentally using reduced representation bisulfite sequencing, CTCF, DNase I, H3K4me3, MNase, and DRIP profiles. "Our comprehensive computational analysis helps the CRISPR-Cas9 community better understand the relationship between epigenetic features and CRISPR-Cas9 off-target activity," the authors write, noting that "[a]s a practical research contribution, we make the off-target dataset containing all 19 epigenetic features available to the research community."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.